Study Details
A Dose Escalation Study of ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Clinicaltrials.gov ID
Astellas Study ID
8273-CL-0102
EudraCT ID
N/A
Condition
Non Small Cell Lung Cancer
Phase
Phase 1
Age
18 years - N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Apr 2014 - Feb 2019
Masking
None (Open Label)
Enrollment number
133
An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Dose Escalation Study of ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site US10001
Boston, United States, 02215
Site US10011
Boston, United States, 02215
Site US10002
Nashville, United States, 37232
Site US10009
Philadelphia, United States, 19104
Site US10006
Baltimore, United States, 21231
Site US10003
Fairfax, United States, 22031
Site US10012
Boston, United States, 02114
Site US10004
Chapel Hill, United States, 27599
Site US10007
Seattle, United States, 98104
Site US10008
New York, United States, 10065
Site US10005
Cleveland, United States, 44106
Site US10010
Washington, United States, 20007-2113